TY - BOOK ID - 146220015 TI - Botulinum Toxin Treatment for Pain and Inflammation in Functional Urological Disorders PY - 2020 PB - Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute DB - UniCat KW - Medicine KW - urethra KW - onabotulinumtoxinA KW - voiding KW - therapeutic outcome KW - lower urinary tract symptoms KW - botulinum toxin KW - benign prostatic hyperplasia KW - prostatitis KW - inflammation KW - Botulinum toxin KW - chronic prostatitis KW - interstitial cystitis KW - treatment KW - bladder pain KW - botulinum toxin A KW - predictor KW - maximal bladder capacity KW - hydrodistention KW - urethral sphincter KW - urethral sphincter dysfunction KW - urodynamics KW - drug delivery KW - overactive bladder KW - painful bladder syndrome KW - molecular mechanism KW - chronic pelvic pain syndrome KW - pelvic pain KW - functional urology disorder KW - human KW - network meta-analysis KW - OnabotulinumtoxinA KW - peripheral tibial nerve stimulation KW - sacral neuromodulation KW - bladder KW - sensation KW - therapy KW - pathophysiology KW - diabetes mellitus KW - mid-urethral sling KW - antimuscarinics KW - urinary incontinence KW - functional urological disorders KW - pain KW - neurogenic detrusor overactivity KW - urethra KW - onabotulinumtoxinA KW - voiding KW - therapeutic outcome KW - lower urinary tract symptoms KW - botulinum toxin KW - benign prostatic hyperplasia KW - prostatitis KW - inflammation KW - Botulinum toxin KW - chronic prostatitis KW - interstitial cystitis KW - treatment KW - bladder pain KW - botulinum toxin A KW - predictor KW - maximal bladder capacity KW - hydrodistention KW - urethral sphincter KW - urethral sphincter dysfunction KW - urodynamics KW - drug delivery KW - overactive bladder KW - painful bladder syndrome KW - molecular mechanism KW - chronic pelvic pain syndrome KW - pelvic pain KW - functional urology disorder KW - human KW - network meta-analysis KW - OnabotulinumtoxinA KW - peripheral tibial nerve stimulation KW - sacral neuromodulation KW - bladder KW - sensation KW - therapy KW - pathophysiology KW - diabetes mellitus KW - mid-urethral sling KW - antimuscarinics KW - urinary incontinence KW - functional urological disorders KW - pain KW - neurogenic detrusor overactivity UR - https://www.unicat.be/uniCat?func=search&query=sysid:146220015 AB - The botulinum toxin has been widely applied in the treatment of functional urological diseases, such as overactive bladder, neurogenic detrusor overactivity, interstitial cystitis, and chronic pelvic pain syndrome. Evidence has shown that the botulinum toxin not only affects the release of neuropeptides from motor nerve endings, but also connects sensory nerves to the central nervous system. Inflammation in the central nervous system can be reduced after botulinum toxin treatment. The scope of therapeutic targets involves detrusor overactivity, sensory disorders, bladder pain and pelvic pain, and inflammatory disorders of the bladder, prostate, and bladder outlet. Although the actual pathophysiological mechanism of the action of the botulinum toxin has not been completely demonstrated, an anti-inflammation effect might be the predominant therapeutic mechanism for functional urological disorders such as an overactive bladder, bladder hypersensitivity, interstitial cystitis, chronic pelvic pain syndrome, chronic prostatitis, and lower urinary tract symptoms/benign prostatic hyperplasia. This Special Issue of Toxins covers the therapeutic potentials of the botulinum toxin on lower urinary tract dysfunctions, with emphasis on the mechanism of pharmacological action and clinical effects. ER -